



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

[illegible]

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international collections under the PCT.

AA	Arabic	CA	Chinese	FR	French	MA	Malay
AB	Azerbaijani	CH	Chinese	GB	English	MB	Mandarin
AC	Armenian	CI	Chinese	GR	Greek	MD	Moldovan
AD	Adyghe	CM	Chinese	HR	Croatian	MG	Malagasy
AE	Arabic	CU	Cuban	IE	Irish	MC	Montenegrin
AF	Afghan	DE	German	IT	Italian	MD	Moldovan
AG	Agave	DK	Danish	JP	Japanese	MO	Moldovan
AH	Azerbaijani	EE	Estonian	KA	Kazakh	MP	Malay
AI	Azerbaijani	ES	Spanish	KE	Kisumu People's Republic of Kenya	MR	Malay
AJ	Azerbaijani	ET	Ethiopian	KG	Kyrgyz	MS	Malay
AK	Azerbaijani	FI	Finnish	KH	Khmer	MT	Maltese
AL	Albanian	FO	Faroese	KN	Kannada	NA	Norwegian
AM	Armenian	GA	Georgian	LA	Lao	NE	Nepali
AN	Azerbaijani	GB	English	LB	Lebanese	NG	Nigerian
AO	Azerbaijani	GR	Greek	LI	Lithuanian	NI	Nicaraguan
AP	Azerbaijani	HR	Croatian	LU	Luxembourg	NO	Norwegian
AQ	Azerbaijani	IE	Irish	LV	Latvian	NU	Norwegian
AR	Arabic	IS	Israeli	LY	Libyan	NU	Norwegian
AS	Azerbaijani	IT	Italian	MA	Malay	NU	Norwegian
AT	Azerbaijani	JP	Japanese	MC	Montenegrin	NU	Norwegian
AV	Azerbaijani	KA	Kazakh	MD	Moldovan	NU	Norwegian
AW	Azerbaijani	KG	Kyrgyz	ME	Montenegrin	NU	Norwegian
AX	Azerbaijani	KN	Kannada	ML	Malay	NU	Norwegian
AY	Azerbaijani	LA	Lao	MM	Malay	NU	Norwegian
AZ	Azerbaijani	LB	Lebanese	MO	Moldovan	NU	Norwegian
BA	Bosnian	LC	Lebanese	MP	Malay	NU	Norwegian
BB	Bosnian	LI	Lithuanian	MR	Montenegrin	NU	Norwegian
BC	Bosnian	LU	Luxembourg	MS	Malay	NU	Norwegian
BD	Bosnian	LV	Latvian	MT	Maltese	NU	Norwegian
BE	Bosnian	LY	Libyan	MC	Montenegrin	NU	Norwegian
BF	Bosnian	MA	Malay	MD	Moldovan	NU	Norwegian
BG	Bosnian	KG	Kyrgyz	ME	Montenegrin	NU	Norwegian
BH	Bosnian	KN	Kannada	ML	Malay	NU	Norwegian
BI	Bosnian	LA	Lao	MM	Malay	NU	Norwegian
BJ	Bosnian	LB	Lebanese	MO	Moldovan	NU	Norwegian
BK	Bosnian	LI	Lithuanian	MP	Malay	NU	Norwegian
BL	Bosnian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
BM	Bosnian	LV	Latvian	MS	Malay	NU	Norwegian
BN	Bosnian	LY	Libyan	MT	Maltese	NU	Norwegian
BO	Bosnian	MA	Malay	MC	Montenegrin	NU	Norwegian
BP	Bosnian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
BR	Bosnian	KN	Kannada	ME	Montenegrin	NU	Norwegian
BS	Bosnian	LA	Lao	ML	Malay	NU	Norwegian
BT	Bosnian	LB	Lebanese	MM	Malay	NU	Norwegian
BU	Bosnian	LC	Lebanese	MO	Moldovan	NU	Norwegian
BV	Bosnian	LI	Lithuanian	MP	Malay	NU	Norwegian
BW	Bosnian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
BX	Bosnian	LV	Latvian	MS	Malay	NU	Norwegian
BY	Bosnian	LY	Libyan	MT	Maltese	NU	Norwegian
BZ	Bosnian	MA	Malay	MC	Montenegrin	NU	Norwegian
CA	Chinese	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
CB	Chinese	KN	Kannada	ME	Montenegrin	NU	Norwegian
CC	Chinese	LA	Lao	ML	Malay	NU	Norwegian
CD	Chinese	LB	Lebanese	MM	Malay	NU	Norwegian
CE	Chinese	LC	Lebanese	MO	Moldovan	NU	Norwegian
CF	Chinese	LI	Lithuanian	MP	Malay	NU	Norwegian
CG	Chinese	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
CH	Chinese	LV	Latvian	MS	Malay	NU	Norwegian
CI	Chinese	LY	Libyan	MT	Maltese	NU	Norwegian
CJ	Chinese	MA	Malay	MC	Montenegrin	NU	Norwegian
CK	Chinese	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
CL	Chinese	KN	Kannada	ME	Montenegrin	NU	Norwegian
CM	Chinese	LA	Lao	ML	Malay	NU	Norwegian
CN	Chinese	LB	Lebanese	MM	Malay	NU	Norwegian
CO	Chinese	LC	Lebanese	MO	Moldovan	NU	Norwegian
CP	Chinese	LI	Lithuanian	MP	Malay	NU	Norwegian
CQ	Chinese	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
CR	Chinese	LV	Latvian	MS	Malay	NU	Norwegian
CS	Chinese	LY	Libyan	MT	Maltese	NU	Norwegian
CT	Chinese	MA	Malay	MC	Montenegrin	NU	Norwegian
CU	Chinese	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
CV	Chinese	KN	Kannada	ME	Montenegrin	NU	Norwegian
CW	Chinese	LA	Lao	ML	Malay	NU	Norwegian
CX	Chinese	LB	Lebanese	MM	Malay	NU	Norwegian
CY	Chinese	LC	Lebanese	MO	Moldovan	NU	Norwegian
CZ	Chinese	LI	Lithuanian	MP	Malay	NU	Norwegian
DA	Danish	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
DB	Danish	LV	Latvian	MS	Malay	NU	Norwegian
DC	Danish	LY	Libyan	MT	Maltese	NU	Norwegian
DD	Danish	MA	Malay	MC	Montenegrin	NU	Norwegian
DE	German	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
DF	German	KN	Kannada	ME	Montenegrin	NU	Norwegian
DG	German	LA	Lao	ML	Malay	NU	Norwegian
DH	German	LB	Lebanese	MM	Malay	NU	Norwegian
DI	German	LC	Lebanese	MO	Moldovan	NU	Norwegian
DJ	German	LI	Lithuanian	MP	Malay	NU	Norwegian
DK	Danish	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
DL	Danish	LV	Latvian	MS	Malay	NU	Norwegian
DM	Danish	LY	Libyan	MT	Maltese	NU	Norwegian
DN	Danish	MA	Malay	MC	Montenegrin	NU	Norwegian
DO	Danish	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
DP	Danish	KN	Kannada	ME	Montenegrin	NU	Norwegian
DQ	Danish	LA	Lao	ML	Malay	NU	Norwegian
DR	Danish	LB	Lebanese	MM	Malay	NU	Norwegian
DS	Danish	LC	Lebanese	MO	Moldovan	NU	Norwegian
DT	Danish	LI	Lithuanian	MP	Malay	NU	Norwegian
DU	Danish	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
DV	Danish	LV	Latvian	MS	Malay	NU	Norwegian
DW	Danish	LY	Libyan	MT	Maltese	NU	Norwegian
DX	Danish	MA	Malay	MC	Montenegrin	NU	Norwegian
DY	Danish	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
DZ	Danish	KN	Kannada	ME	Montenegrin	NU	Norwegian
EA	English	LA	Lao	ML	Malay	NU	Norwegian
EB	English	LB	Lebanese	MM	Malay	NU	Norwegian
EC	English	LC	Lebanese	MO	Moldovan	NU	Norwegian
ED	English	LI	Lithuanian	MP	Malay	NU	Norwegian
EE	Estonian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
EF	Estonian	LV	Latvian	MS	Malay	NU	Norwegian
EG	English	LY	Libyan	MT	Maltese	NU	Norwegian
EH	English	MA	Malay	MC	Montenegrin	NU	Norwegian
EI	English	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
EJ	English	KN	Kannada	ME	Montenegrin	NU	Norwegian
EK	English	LA	Lao	ML	Malay	NU	Norwegian
EL	English	LB	Lebanese	MM	Malay	NU	Norwegian
EM	English	LC	Lebanese	MO	Moldovan	NU	Norwegian
EN	English	LI	Lithuanian	MP	Malay	NU	Norwegian
EO	English	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
EP	English	LV	Latvian	MS	Malay	NU	Norwegian
EQ	English	LY	Libyan	MT	Maltese	NU	Norwegian
ER	English	MA	Malay	MC	Montenegrin	NU	Norwegian
ES	Spanish	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
ET	Ethiopian	KN	Kannada	ME	Montenegrin	NU	Norwegian
EU	English	LA	Lao	ML	Malay	NU	Norwegian
EV	English	LB	Lebanese	MM	Malay	NU	Norwegian
EW	English	LC	Lebanese	MO	Moldovan	NU	Norwegian
EX	English	LI	Lithuanian	MP	Malay	NU	Norwegian
EY	English	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
EZ	English	LV	Latvian	MS	Malay	NU	Norwegian
FA	French	LY	Libyan	MT	Maltese	NU	Norwegian
FB	French	MA	Malay	MC	Montenegrin	NU	Norwegian
FC	French	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
FD	French	KN	Kannada	ME	Montenegrin	NU	Norwegian
FE	French	LA	Lao	ML	Malay	NU	Norwegian
FF	French	LB	Lebanese	MM	Malay	NU	Norwegian
FG	French	LC	Lebanese	MO	Moldovan	NU	Norwegian
FH	French	LI	Lithuanian	MP	Malay	NU	Norwegian
FI	Finnish	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
FJ	Finnish	LV	Latvian	MS	Malay	NU	Norwegian
FK	Finnish	LY	Libyan	MT	Maltese	NU	Norwegian
FL	Finnish	MA	Malay	MC	Montenegrin	NU	Norwegian
FM	Finnish	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
FN	Finnish	KN	Kannada	ME	Montenegrin	NU	Norwegian
FO	Faroese	LA	Lao	ML	Malay	NU	Norwegian
FP	Faroese	LB	Lebanese	MM	Malay	NU	Norwegian
FQ	Faroese	LC	Lebanese	MO	Moldovan	NU	Norwegian
FR	French	LI	Lithuanian	MP	Malay	NU	Norwegian
FS	French	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
FT	French	LV	Latvian	MS	Malay	NU	Norwegian
FU	French	LY	Libyan	MT	Maltese	NU	Norwegian
FV	French	MA	Malay	MC	Montenegrin	NU	Norwegian
FW	French	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
FX	French	KN	Kannada	ME	Montenegrin	NU	Norwegian
FY	French	LA	Lao	ML	Malay	NU	Norwegian
FZ	French	LB	Lebanese	MM	Malay	NU	Norwegian
GA	Georgian	LC	Lebanese	MO	Moldovan	NU	Norwegian
GB	English	LI	Lithuanian	MP	Malay	NU	Norwegian
GC	Georgian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
GD	Georgian	LV	Latvian	MS	Malay	NU	Norwegian
GE	Georgian	LY	Libyan	MT	Maltese	NU	Norwegian
GF	Georgian	MA	Malay	MC	Montenegrin	NU	Norwegian
GG	Georgian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
GH	Ghanaian	KN	Kannada	ME	Montenegrin	NU	Norwegian
GI	Georgian	LA	Lao	ML	Malay	NU	Norwegian
GJ	Georgian	LB	Lebanese	MM	Malay	NU	Norwegian
GK	Georgian	LC	Lebanese	MO	Moldovan	NU	Norwegian
GL	Georgian	LI	Lithuanian	MP	Malay	NU	Norwegian
GM	Georgian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
GN	Georgian	LV	Latvian	MS	Malay	NU	Norwegian
GO	Georgian	LY	Libyan	MT	Maltese	NU	Norwegian
GP	Georgian	MA	Malay	MC	Montenegrin	NU	Norwegian
GQ	Georgian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
GR	Georgian	KN	Kannada	ME	Montenegrin	NU	Norwegian
GS	Georgian	LA	Lao	ML	Malay	NU	Norwegian
GT	Georgian	LB	Lebanese	MM	Malay	NU	Norwegian
GU	Georgian	LC	Lebanese	MO	Moldovan	NU	Norwegian
GV	Georgian	LI	Lithuanian	MP	Malay	NU	Norwegian
GW	Georgian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
GX	Georgian	LV	Latvian	MS	Malay	NU	Norwegian
GY	Georgian	LY	Libyan	MT	Maltese	NU	Norwegian
GZ	Georgian	MA	Malay	MC	Montenegrin	NU	Norwegian
HA	Haitian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
HB	Haitian	KN	Kannada	ME	Montenegrin	NU	Norwegian
HC	Haitian	LA	Lao	ML	Malay	NU	Norwegian
HD	Haitian	LB	Lebanese	MM	Malay	NU	Norwegian
HE	Haitian	LC	Lebanese	MO	Moldovan	NU	Norwegian
HF	Haitian	LI	Lithuanian	MP	Malay	NU	Norwegian
HG	Haitian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
HH	Haitian	LV	Latvian	MS	Malay	NU	Norwegian
HI	Haitian	LY	Libyan	MT	Maltese	NU	Norwegian
HJ	Haitian	MA	Malay	MC	Montenegrin	NU	Norwegian
HK	Haitian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
HL	Haitian	KN	Kannada	ME	Montenegrin	NU	Norwegian
HM	Haitian	LA	Lao	ML	Malay	NU	Norwegian
HN	Haitian	LB	Lebanese	MM	Malay	NU	Norwegian
HO	Haitian	LC	Lebanese	MO	Moldovan	NU	Norwegian
HP	Haitian	LI	Lithuanian	MP	Malay	NU	Norwegian
HQ	Haitian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
HR	Croatian	LV	Latvian	MS	Malay	NU	Norwegian
HS	Haitian	LY	Libyan	MT	Maltese	NU	Norwegian
HT	Haitian	MA	Malay	MC	Montenegrin	NU	Norwegian
HU	Hungarian	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
HV	Hungarian	KN	Kannada	ME	Montenegrin	NU	Norwegian
HW	Hungarian	LA	Lao	ML	Malay	NU	Norwegian
HX	Hungarian	LB	Lebanese	MM	Malay	NU	Norwegian
HY	Hungarian	LC	Lebanese	MO	Moldovan	NU	Norwegian
HZ	Hungarian	LI	Lithuanian	MP	Malay	NU	Norwegian
IA	Indonesian	LU	Luxembourg	MR	Montenegrin	NU	Norwegian
IB	Indonesian	LV	Latvian	MS	Malay	NU	Norwegian
IC	Indonesian	LY	Libyan	MT	Maltese	NU	Norwegian
ID	Indonesian	MA	Malay	MC	Montenegrin	NU	Norwegian
IE	Irish	KG	Kyrgyz	MD	Moldovan	NU	Norwegian
IF	Irish	KN	Kannada	ME	Montenegrin	NU	Norwegian
IG	Irish	LA	Lao	ML	Malay	NU	Norwegian
IH	Irish	LB	Lebanese	MM	Malay	NU	Norwegian
II	Irish	LC	Lebanese	MO	Mold		

CHEMICAL METHOD FOR THE ANALYSIS OF DNA SEQUENCES

5 This invention relates to a novel method for identifying a base in a target position in a DNA sequence.

In the diagnostic or forensic use of DNA analysis, full sequencing of target DNA may be unnecessary where the detection of a single base variation or mismatch is sufficient to provide the required information. Such a single base variation or mismatch may for example arise from a point mutation or, in fact, any deletion or insertion of genetic material where the detection of the first irregular base in the sequence will give the required diagnostic information. Thus, Allelic Specific PCR has been developed whereby PCR (polymerase chain reaction) is carried out on a sample using a pair of primers for the target DNA one of which is relatively short and will hybridise to one allelic locus of the DNA but not to the other allelic sequence. Failure to amplify is thus indicative that the non-hybridising allele of the DNA was present but unfortunately the conditions required to obtain reliable hybridisation to the normal DNA are difficult to achieve in practice.

It has been proposed to carry out PCR using probes hybridising to positions away from the target mutation or area of allelic variation, followed by use of a labelled probe which will not hybridise to the mutated region or area of allelic variation. However, this also commonly gives false negatives.

A method of detecting allele-specific DNA called the Ligation Chain Reaction (LCR) has recently been developed and has been reviewed by F. Barang (PCR Methods and Applications Vol.1, 5-16). Two different oligonucleotides, which hybridise adjacent to each other on complementary DNA, are required and the products of

SUBSTITUTE SHEET

LCR need to be separated on a polyacrylamide gel before a result can be determined.

Full length sequencing, particularly solid phase sequencing, as described in WO 89/0282 gives accurate results but is more demanding and may thus not be appropriate for diagnostic screening in some instances.

The present invention is based on the concept of using a polymerase reaction on four aliquots of amplified and immobilised DNA of interest in single stranded form. Each aliquot uses the same specific extension primer and a different dideoxynucleotide but no dideoxynucleotides so that only the dideoxynucleotide complementary to the base in the target position is incorporated; the target position being directly adjacent to the 3' end of the specific extension primer hybridising to the DNA. Put another way, the target position on the immobilised strand is immediately 3' of where the specific primer hybridises to the DNA. Chain extension using normal dideoxynucleotides is then effected (a so-called chase reaction) using the specific primer so that the dideoxy-blocked DNA will remain unreacted while the un-blocked DNA will form double stranded DNA. Various methods may then be used to distinguish double stranded DNA from non-extended DNA, ie substantially single stranded DNA, and thus enable the base in the target position to be identified.

The invention thus provides a method of identification of the base in a target position in a DNA sequence wherein sample DNA is subjected to amplification; the amplified DNA is immobilised and then subjected to strand separation, the non-immobilised strand being removed and an extension primer, which hybridises to the immobilised DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilised single stranded DNA is then subjected to a polymerase reaction in the presence of a dideoxynucleotide, each aliquot using a different

SUBSTITUTE SHEET

5 dideoxynucleotide whereby only the dideoxynucleotide complementary to the base in the target position becomes incorporated; the four aliquots are then subjected to extension in the presence of all four dideoxynucleotides, whereby in each aliquot the DNA which has not reacted with the dideoxynucleotide is extended to form double stranded DNA while the dideoxy-blocked DNA remains as non-extended DNA; followed by identification of the double stranded and/or non-extended DNA to indicate which dideoxynucleotide was incorporated and hence which base was present in the target position.

10 The term dideoxynucleotide as used herein includes all 2'-dideoxynucleotides in which the 3'-hydroxyl group is absent or modified and thus, while able to be added to the primer in the presence of the polymerase, is unable to enter into a subsequent polymerisation reaction.

15 Preferably, the sample DNA is amplified *in vitro* by PCR although amplification by other methods may be used such as *in vitro* Self Sustained Sequence Replication (SSR) or *in vitro* in a vector, and, if desired, *in vitro* and *in vitro* amplification may be used in combination. Whichever method of amplification is used it is desirable that the amplified DNA becomes immobilised or
 20 is provided with means for attachment to a solid support. For example, a PCR primer may be immobilised or be provided with means for attachment to a solid support. Also, a vector may comprise means for attachment to a solid support adjacent the site of insertion of the sample DNA such that the amplified sample DNA and the means for attachment may be excised together.

25 In the PCR method a pair of polymerization primers specific to known sequences of the target DNA are selected, one hybridising at or near the 5' end of one of the strands and the other at or near the 5' end of the complementary strand such that in the presence of a
 30

SUBSTITUTE SHEET

35 polymerase, each primer produces a DNA sequence extending the full length of the target DNA template. If the DNA so produced is then subjected to strand separation, typically by melting at a temperature of
 40

5 about 90°C, the newly formed single stranded DNA sequences will hybridise to excess primer present in the mixture, usually after reducing the temperature to the range suitable for annealing, whereupon in the presence of the polymerase, further DNA strands are synthesised, this time extending only between the terminal of the two primers. The polymerase is preferably capable of surviving the high temperature used in the strand separation step, a suitable thermostable polymerase, namely Taq, having recently become available. If an excess of the two primers and of nucleotides needed for DNA synthesis is maintained in the medium, it is possible to operate a repeated cyclic process in which the separate strands are synthesised, separated, annealed to primer and new strands synthesised, merely
 10 by raising and lowering the temperature between the optimal temperatures for each of the above stages. In this way, it is found that amplification of the original target DNA can be exponential and million-fold increases of concentration can be effected in a relatively short
 15 time.

20 It is desirable that when PCR is used its effectiveness is assessed, e.g. to determine whether or not sufficient DNA has been formed to give clear results with a relatively low level of background. Various tests are known in the art but we prefer to use the solid phase approach we described earlier for detection
 25 of immobilized amplified nucleic acids, designated DIANA (PCT/EP93/00454), which has been used for example in its preferred embodiment in the colorimetric detection of *in vitro* amplified DNA. The assay is based on the use of a biotinylated or otherwise functionalised PCR primer, which is used to capture *in vitro* amplified material on,

SUBSTITUTE SHEET

for example, streptavidin-coated magnetic beads. The other PCR primer contains a "handle", such as a λ g operator sequence, allowing colorimetric detection of the captured DNA using a λ gI repressor- β -galactosidase fusion protein. (Wahlberg, J., Lundberg, J., Miltman, T., and Uhlen, K. (1990) "General colorimetric method for DNA diagnostics allowing direct solid-phase genomic sequencing of the positive samples." Proc. Natl. Acad. Sci U.S.A. 87, 6569-6573). The preferred form of the qualitative DIANA assay combines the advantages of the PCR method with the high specificity and stability of the biotin-streptavidin system and the simplicity of a colorimetric detection based on β -galactosidase. The strong interaction between biotin and streptavidin ($K_d=10^{-6}$ M) accentuates the efficiency of the system. The magnetic beads as solid support ensure that no centrifugations, filtrations or precipitations are needed (T. Miltman, S. Stahl, E. Hornes and K. Uhlen Nucl. Acids Res. 17, 4937 (1989)). However, it is preferred in the method according to the present invention to use the same PCR primer both as the means of immobilisation and for the incorporation of the λ g operator sequence.

A number of proteins are known which bind to specific DNA sequences and are often involved in genetic processes such as switching operators on and off. One such protein is the λ g repressor λ gI which reacts with the λ g operator (λ gOP) to inhibit transcription. Thus, if the recognition site is the DNA sequence λ gOP, the label can be attached via the protein λ gI. It is particularly convenient to devise a fusion protein of a DNA binding protein such as λ gI with a further protein which can be subsequently used for detection for example using methods based on colour fluorescence or chemiluminescence. Examples of such proteins are β -galactosidase, alkaline phosphatase and peroxidase. It is preferred to use as a label a λ gI repressor-

SUBSTITUTE SHEET

β -galactosidase fusion protein which recognises a 21 base pair λ g operator sequence introduced at the end of the amplified DNA. The λ g operator sequence may be introduced for example by one of the PCR primers if used, preferably the immobilised primer, or the sequence may be in an amplification vector in a suitable position for excision with the amplified sample DNA. The fusion protein will bind to the λ g OP sequence of the DNA and the addition of OMFG (ortho-nitrophenyl- β -D-galactoside) will lead to a colour formation which can be assessed spectrophotometrically. Use of this fusion protein and OMFG (ortho-nitrophenyl- β -D-galactoside) allows for a fast simple colorimetric assay which does not have the safety problems associated with using radiolabels. IPTG (n-isopropyl- β -D-thiogalactopyranoside) for example, can be added to release the fusion protein from the DNA.

Two-stage PCR (using nested primers), as described in our co-pending application PCT/EP90/00454, may be used to enhance the signal to noise ratio and thereby increase the sensitivity of the method according to the invention. By such preliminary amplification, the concentration of target DNA is greatly increased with respect to other DNA which may be present in the sample and a second-stage amplification with at least one primer specific to a different sequence of the target DNA significantly enhances the signal due to the target DNA relative to the 'background noise'.

Any suitable polymerase may be used, although it is preferred to use a thermophilic enzyme such as Taq polymerase to permit the repeated temperature cycling without having to add further polymerase, e.g. Klenow fragment, in each cycle of PCR.

Regardless of whether one-stage or two stage PCR is performed, the efficiency of the PCR is not critical since the invention relies on the distinct difference between the aliquots. However, as mentioned above, it is preferred to run an initial qualitative DIANA as a

SUBSTITUTE SHEET

check for the presence or absence of amplified DNA.

Immobilisation of the amplified DNA may take place as part of PCR amplification itself, as where one or more primers are attached to a support, or alternatively one or more of the PCR primers may carry a functional group permitting subsequent immobilisation, eg. a biotin or thiol group. Immobilisation by the 5' end of a primer allows the strand of DNA emanating from that primer to be attached to a solid support and have its 3' end remote from the support and available for subsequent hybridisation with the extension primer and chain extension by polymerase.

The present invention includes a particularly useful primer which comprises, reading 5' to 3', means permitting immobilisation of said primer, a sequence which is bound by a DNA binding protein, and a sequence capable of hybridising at or near the 5' end of a strand of target DNA. Use of such a primer allows for immobilisation and the ability to determine whether or not double stranded DNA is formed in a polymerisation step substantially up to the point of immobilisation. It will be clear that several nucleotides may intervene between the means permitting immobilisation and the sequence which is bound by a DNA binding protein or between that sequence and the sequence capable of hybridising to target DNA.

Preferably, the means permitting immobilisation is biotin although other functional groups, such as thiol groups, may be used. However, biotin is preferred because of its strong interaction with streptavidin and the relative ease by which it can be incorporated into a primer. The sequence which is bound by a DNA binding protein is preferably the *lac* operator which is reversibly bound by the *lac* I repressor protein.

The solid support may conveniently take the form of microtitre wells, which are advantageously in the conventional 8 x 12 format, or dipsticks which may be

made of polystyrene activated to bind the primer DNA (K. Aker, Doctoral Thesis, Royal Institute of Technology, Stockholm, Sweden, 1988). The support may also comprise particles, fibres or capillaries made, for example, of agarose, cellulose, alginate, teflon or polystyrene. The support may also comprise magnetic particles eg the superparamagnetic beads produced by Dynal AS (Oslo, Norway).

The solid support may carry functional groups such as hydroxyl, carboxyl, aldehyde or amino groups, or other moieties such as avidin or streptavidin, for the attachment of primers. These may in general be provided by treating the support to provide a surface coating of a polymer carrying one of such functional groups. e.g. polyurethane together with a polyglycol to provide hydroxyl groups, or a cellulose derivative to provide hydroxyl groups, a polymer or copolymer of acrylic acid or methacrylic acid to provide carboxyl groups or an aminoalkylated polymer to provide amino groups. US Patent No. 4654267 describes the introduction of many such surface coatings.

The assay technique is very simple and rapid, thus making it easy to automate by using a robot apparatus where a large number of samples may be rapidly analysed. Since the preferred detection and quantification is based on a colorimetric reaction a visual analysis is often sufficient for evaluation.

The target DNA may be cDNA synthesised from RNA in the sample and the method of the invention is thus applicable to diagnosis on the basis of characteristic RNA. Such preliminary synthesis can be carried out by a preliminary treatment with a reverse transcriptase, conveniently in the same system of buffers and bases of subsequent PCR steps if used. Since the PCR procedure requires heating to effect strand separation, the reverse transcriptase will be inactivated in the first PCR cycle. When mRNA is the sample nucleic acid, it may

be advantageous to submit the initial sample, e.g. a serum sample, to treatment with an immobilised polydT oligonucleotide in order to retrieve all mRNA via the terminal polyA sequences thereof. Alternatively, a specific oligonucleotide sequence may be used to retrieve the RNA via a specific RNA sequence. The oligonucleotide can then serve as a primer for cDNA synthesis, as described in International Patent Application PC/93/00304.

PCR has been discussed above as a preferred method of initially amplifying target DNA although the skilled person will appreciate that other methods may be used instead of in combination with PCR. A recent development in amplification techniques which does not require temperature cycling or use of a thermostable polymerase is Self Sustained Sequence Replication (SSR). SSR is modelled on retroviral replication and may be used for amplification (see for example Gingeras, T.R. *et al* PNAS (USA) 87:1874-1878 and Gingeras, T.R. *et al* PCR Methods and Applications Vol. 1, pp 25-33).

Advantageously, the extension primer is sufficiently large to provide appropriate hybridisation with the immobilised strand immediately adjacent the target position, yet still reasonably short in order to avoid unnecessary chemical synthesis. It will be clear to persons skilled in the art that the size of the extension primer and the stability of hybridisation will be dependent to some degree on the ratio of A-T to C-G base pairings, since more hydrogen bonding is available in a C-G pairing. Also, the skilled person will

consider the degree of homology between the extension primer to other parts of the amplified sequence and choose the degree of stringency accordingly. Guidance for such routine experimentation can be found in the literature, for example, Molecular Cloning: a laboratory manual by Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989). The extension primer is preferably added before

SUBSTITUTE SHEET

the sample is divided into four aliquets although it may be added separately to each aliquet. It should be noted that the extension primer may be identical with the PCR primer but preferably it is different, to introduce a further element of specificity into the system.

The polymerase reaction in the presence of dideoxy nucleotides is carried out using a polymerase which will incorporate dideoxynucleotides, e.g. T7 polymerase, Klenow or Sequenase Ver. 2.0 (USB U.S.A.). However, it is known that many polymerases have a proof-reading or error checking ability and that 3' ends available for chain extension are sometimes digested by one or more nucleotides. If such digestion occurs in the method according to the invention the level of background noise increases. In order to avoid this problem it is preferable to use a non proof-reading polymerase, e.g. T7 polymerase or Sequenase. Otherwise it is desirable to add to each aliquot fluoride ions or nucleotide monophosphates which suppress 3' digestion by polymerase.

Identification of the double stranded and/or non-extended DNA is possible via a variety of means. With regard to the double stranded DNA, conventional techniques such as radiolabel incorporation during chain extension are possible but it is preferred to use the Lac operator sequence which is preferably incorporated into the DNA during amplification, as discussed above. Full chain extension creates the double stranded DNA sequence which is bound by the Lac I repressor-galactokinase fusion protein. Bound fusion protein can then be identified colorimetrically as discussed above and this identifies the three aliquets which have been extended, thereby identifying the dideoxy base which was added in the remaining aliquet.

With regard to the non-extended DNA, where extension of the primer was blocked by a dideoxynucleotide, again a number of means for

SUBSTITUTE SHEET

Identification are possible and will be readily apparent to the skilled person. Preferably, a probe which hybridizes downstream of the 3' end of the extension primer is used, as the probe hybridises to the immobilised strand between the site of hybridisation of the extension primer and the 5' end of the immobilised strand. The probe is suitably labelled or provided with means for attaching a label. Such a probe will bind to the single strand DNA but will not bind to the double stranded DNA.

If desired, both double and single stranded DNA can be identified and this provides additional checking for the accuracy of the results. It will usually be desirable to run a control with no dideoxynucleotides and a 'zero control' containing a mixture of all four dideoxynucleotides.

Another means of identification is that disclosed in our co-pending application of even date (Agents ref.: 75.57799) which relates to detection of pyrophosphate released during chain extension. When each nucleotide is incorporated, a pyrophosphate group is split off the nucleotide triphosphate and the remaining nucleotide monophosphate is incorporated at the end of the growing nucleic acid chain. In those aliquots which have not incorporated a chain terminating dideoxynucleotide there is extensive pyrophosphate release during chain extension. This release of pyrophosphate can be measured using luciferin and luciferase which emit light in substantially direct proportion to the amount of pyrophosphate present.

In many diagnostic applications, for example genetic testing for carriers of inherited disease, the sample will contain heterozygous material, that is half the DNA will have one nucleotide at the target position and the other half will have another nucleotide. Thus of the four aliquots used in the method of the invention, two will show a positive signal and two will

SUBSTITUTE SHEET

show half the positive signal. It will be seen therefore that it is desirable to quantitatively determine the amount of label detected in each sample. In the case of a homozygous sample it will be clear that there will be three negative and one positive signal of the four aliquots.

Advantageously, the method according to the present invention may be combined with the method taught in our co-pending patent application of even date (Agents ref.: 75.57466) which uses PCR to introduce loop structures which provide a permanently attached 3' primer at the 3' terminal of a DNA strand of interest. For example, in such a modified method, the extension primer is introduced as part of the 3'-terminal loop structure onto a target sequence of one strand of double stranded DNA which contains the target position, said target sequence having a region A at the 3'-terminus thereof and there being optionally a DNA region B which extends 3' from region A, whereby said double-stranded DNA is subjected to polymerase chain reaction (PCR) amplification using a first primer hybridising to the 3'-terminus of the sequence complementary to the target sequence, which first primer is immobilised or provided with means for attachment to a solid support, and a second primer having a 3'-terminal sequence which hybridises to at least a portion of A and/or B of the target sequence while having at its 5'-end a sequence substantially identical to A, said amplification producing double-stranded target DNA having at the 3'-end of the target sequence, in the following order, the region A, a region capable of forming a loop and a sequence A' complementary to sequence A, thereafter the amplified double-stranded DNA is subjected in immobilised form to strand separation whereby the non-immobilised target strand is liberated and region A' is permitted or caused to hybridise to region A, thereby forming said loop. The 3' end of region A' hybridises

SUBSTITUTE SHEET

immediately adjacent the target position. The dideoxy and extension reactions use the hybridised portion as a primer and the base incorporated at the target position can be identified in any manner, preferably by pyrophosphate release as taught by our co-pending 75.57799 application mentioned above.

The invention also comprises kits which will normally include at least the following components:

- 10 (a) a test specific extension primer which hybridizes to sample DNA so that the target position is directly adjacent to the 3' end of the primer;
- (b) a polymerase;
- 15 (c) deoxynucleotides and dideoxynucleotides; and
- (d) optionally a solid support.
- 20 If the kit is for use with initial PCR amplification then it will also normally include at least the following components:
- (i) a pair of primers for PCR at least one primer having means permitting immobilisation of said primer;

(ii) a polymerase which is preferably heat stable, for example *TaqI* polymerases;

30 (iii) buffers for the PCR reaction; and

(iv) deoxynucleotides.

35 Where an enzyme label is used, the kit will advantageously contain a substrate for the enzyme and other components of a detection system.

Preferably, one of the primers will include both means permitting immobilisation of said primer and a sequence which is bound by protein. A preferred form of primer comprises biotin to act as the means permitting immobilisation, eg to an avidin or streptavidin coated surface, and the tag operator as the means permitting labelling. The kit for carrying out the invention using a preferred primer of the type described above would preferably contain an enzyme label conjugated to the lac I repressor protein; a preferred enzyme label being β -galactosidase.

The invention will now be described by way of non-limiting examples with reference to the drawings in which:

15 Fig.1 shows a protocol for identifying a base in a single target position using the method according to the invention;

Fig.2 shows oligonucleotide primers used in Example 1 together with sample DNA for amplification;

20 Fig.3 shows further oligonucleotide primers used in the Example together with the sample DNA; and

Fig.4 is a graph showing the results obtained in the Example of the method according to the invention.

25 MATERIALS AND METHODS

Bacterial strains and plasmids. *Escherichia coli* RELAM19 (R  ther, U. (1982). pCR 250 which allows rapid chemical sequencing of both strands of its inserts (Nucl. Acids Res., 10, 5765-5722) was used as bacterial host. The plasmid vector used was pCR 28 (Ruitman, T., Stahl, S., Moles, N. and Uhlen, N. (1988) "Approaches to Solid Phase DNA Sequencing", Nucleosides & Nucleotides, 7, 629-638).

35 Synthesis of oligonucleotides. 7 oligonucleotide primers (see figures 2 and 3), RIT 135, RIT 321, RIT 322, RIT 331, RIT 332 and RIT 333, complementary to

regions encoding a part of the active site of the HIV reverse transcriptase gene (RT) (bases 625 to 1165 Myers, G., Korber, B., Berkyovsky, J.A. Smith, R.F. and Pavlakis, G.N. Human Retroviruses and AIDS 1991 (Los Alamos National Laboratory, New Mexico 1991)), were synthesized by phosphoramidite chemistry on an automated DNA synthesis apparatus (Gene Assembler Plus, AMB-Pharmacia, Sweden) as described by the manufacturer. RT222 was biotinylated by using a biotin phosphoramidite (Clontech, Ca, U.S.A.). Purification was performed on a pepRPC 5/5 reversed phase column (XMB-Pharmacia, Sweden).

Enzymes and nucleotides. Restriction enzymes, T4 DNA ligase (XMB-Pharmacia, Sweden), T7 DNA polymerase (XMB-Pharmacia, Sweden), Taq DNA polymerase (Cetus, Ca, U.S.A.) and Sequenase ver 2.0 (USB U.S.A.) were used in accordance with the supplier's recommendations. Deoxy- and dideoxynucleotides were obtained from Boehringer Mannheim, Germany.

PCR cloning

The HIV RT fragment was cloned by amplification from a clinical sample obtained from a patient with HIV-1 (Swedish Bacteriology Laboratory, SBL, Stockholm, Sweden) using 5 pmol each of the oligonucleotides RT131 and RT133 (figure 3) both containing "handles" in order to introduce an upstream Bam HI and a downstream Eco RI recognition sites. The PCR reaction mix contained 200 μ M dNTPs, 20 mM Tris-HCl (pH 8.7), 2 mM MgCl₂, 0.1% Tween 20 and 0.5 units AmpliTaq resulting in a final volume of 50 μ L. The temperature profile was set up by a denaturation step at 95°C for 0.5 min, followed by a primer annealing step at 55°C for 0.5 min, and a final extension step at 72°C for 2 mins. These steps were repeated 30 times using a Gene Amp PCR System, PE 9600 (Perkin Elmer, Ca., U.S.A.). The PCR amplified HIV RT

SUBSTITUTE SHEET

fragment and the pRT 28 vector were both restricted with Bam HI and Eco RI, cut out and purified from agarose and then ligated for 1 hour in room temperature. The construction was transformed into competent

5 E. coli cells and spread on TBAs (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *MOLECULAR CLONING* in *PCR (polymerase chain reaction)*, plates containing IPTG (N-isopropyl- β -D-thiogalactopyranoside), X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) and ampicillin allowing blue/white selection (Langley, E.K. Villarejo, M.R. Fowler, A.V. Zamenhof, P.J. and Zabin, I. (1975).

Proc. Natl. Acad. Sci. U.S.A. 72, 1254-1257). Five white colonies containing the plasmid with a correct insert was confirmed by solid phase sequencing (Hultman, T., Bergh, S., Moka, T. and Uhlen, K. (1991)

"Bidirectional solid-phase sequencing of in vitro amplified plasmid DNA". *Bio Techniques* 10, 84-93).

One of these clones was designated pRT-22 and chosen for further studies. This clone is stored at the Department of Biochemistry, Royal Institute of Technology, Stockholm, Sweden.

Template preparation for DDMMA detected Mini Sequencing

A colony harbouring pRT22-RF was transferred to a vial and lysed at 95°C for 5 min. in 100 μ L Tris-HCl (pH 8.7). 1 μ L lysate was subsequently transferred to a PCR mixture of 5 pmol RT135 and RT132 (biotinylated), 0.25 pmol RT121, 200 μ M dNTPs, 20 mM Tris-HCl (pH 8.7), 2 mM MgCl₂, 0.1% Tween 20 and 0.5 units AmpliTaq to a final volume of 50 μ L. It will be noted that primer RT122 comprises a 5' biotin, for subsequent attachment to a streptavidin coated solid support, and the 21 bases which define the lac Op recognition sequence.

Amplification was performed as above and the resulting PCR product was subsequently immobilised (Hultman, T. Stahl, S., Hornes, E. and Uhlen, K. (1989) "Direct solid phase sequencing of genomic and plasmid DNA using

SUBSTITUTE SHEET

magnetic beads as solid support". Nucl. acids Res. 17, 4977-4986) on prewashed streptavidin coated paramagnetic beads, (Isa, T., Vardal, F., Nustad, K., et al. (1988). "Monoclonal, magnetic polymer particles: and their use in separation of cells and subcellular components and in the study of lysozyme function in vitro". Journal of Molecular Recognition 1, 9-18) Dynabeads M280-streptavidin (DynaL AS, Norway), prewashed with binding solution according to manufacturer. After

10 immobilization, the beads were rinsed with 50 μ l binding-washing solution and assayed for bound DNA. The beads with the immobilized DNA were mixed with 50 μ l of the fusion protein, lacI- β -galactosidase (DynaL AS, Norway), and incubated for 20 minutes. Excess of the fusion protein was removed by washing the beads 4 times with DYANA buffer (DynaL AS, Norway) and changing to new tubes in the last step in order to avoid background due to coating of the walls. 100 μ l of chromogenic substrate, ortho-nitrophenyl- β -D-galactoside (ONPG, 1.25 mg/ml), was added and after 5 min. the reaction was stopped by an addition of 100 μ l 1M Na₂CO₃ and the supernatant was analyzed in an EAR3400A ELISA plate reader (BMG-lab instruments, Austria) by measuring the absorbance at 405 nm. The strands were separated by melting by incubation with 20 μ l 0.1 M NaOH for 5 min. generating single stranded immobilized DNA template, which was once again washed with 50 μ l binding solution, 50 μ l 1 x TE. The primer annealing was performed in 8 mM MgCl₂ and 20 mM Tris-HCl (pH 7.5) with the use of 1 pmol EXTAP2 (Figure 2) in a volume of 13 μ l by heating to 65°C for 5 min. and then placed in room temperature for 10 min.

Mini Sequencing reactions

Six separate extension reactions with respect to the appropriate dideoxynucleotide were set up (one with

SUBSTITUTE SHEET

only dGMP, one with only dCTP, one with only dATP, one with only dTTP, one with all four dNTPs present and one without any of dNTPs) in a total of 10 μ l containing 2 μ l of the annealing mixture, 17 mM Tris-HCl (pH 7.5), 6 mM MgCl₂, 1 mM DTT, 1 μ M of the appropriate dideoxynucleotide and 0.13 units of Sequase ver. 2. A schematic outline of the experiment is shown in figure 1. The dideoxy incorporation was performed at room temperature for 5 mins. and stopped by adding 20 μ l 0.5M EDTA. Thereafter the beads were washed twice with 30 μ l 10 mM Tris-HCl (pH 7.5). In the following extension step 200 μ l dNTP concentration was used together with 25 mM Tris-HCl (pH 7.5), 12.5 mM MgCl₂, 1 mM DTT and 0.13 units Sequase in a total of 10 μ l. In the aliquots where a dideoxynucleotide had not been incorporated, the Sequase leads to a chain extension and to full double stranded DNA being attached to the beads. After a 5 min. incubation in room temperature 20 μ l 0.5 M EDTA was added and the beads were washed with 40 μ l DYANA buffer (DynaL AS, Norway) (0.1 M Tris-HCl (pH 7.5), 0.15 M NaCl, 0.1% Tween 20, 1 mM MgCl₂ and 10 mM β -mercaptoethanol).

Detection by DYANA

The results were detected by DYANA (Wehlberg, J., Lundeborg, V., Hultman, T. and Uhlen, M. (1990) "General colorimetric method for DNA diagnostics allowing direct solid-phase genomic sequencing of the positive samples." Proc. Natl. Acad. Sci U.S.A. 87, 6569-6573). The beads with the immobilized DNA were mixed with 90 μ l of the fusion protein, lacI- β -galactosidase (DynaL AS, Norway), and incubated for 20 minutes. Excess of the fusion protein was removed by washing the beads 4 times with DYANA buffer (DynaL AS, Norway) and changing to new tubes in the last step in order to avoid background due to coating of the walls.

SUBSTITUTE SHEET

100 μ l of chromogenic substrate, ortho-nitrophenyl- β -D-galactoside (ONPG, 1.25 mg/ml), was added and after 6 min. the reaction was stopped by an addition of 100 μ l 1M Na_2CO_3 and the supernatant was analyzed in an EMAS40AT ELISA plate reader (Ströbel-Instrumente, Austria) by measuring the absorbance at 405 nm. The results are shown in figure 4. The assay show that a low signal is obtained when all four dideoxynucleotides (ddNTPs) are used as well as when only ddATP is used. Since the complementary base next to the 3'-end of the sequencing primer is a dideoxythymidine, the result demonstrates that the assay can be used to detect a base sequence at a specific point.

15 Example 2

Template preparation

A HIV reverse transcriptase gene fragment from a patient showing AZT resistance was PCR-cloned (Pettersson, B, *et al* unpublished data) into the vector pRIT 28 by using the primers RIT 331 and RIT 333. *Escherichia coli* strain was transformed and blue/white selectivity was used (Langley *et al*, (1978) *loc. cit.*) PCR amplification was carried out by lysing a bacterial colony in 10 μ l 20 mM Tris-Cl (pH 8.7) at 99°C for 5 minutes. Then 1 μ l of the lysate was added to 5 μ l primer set A, 200 μ M dNTP, 20 mM Tris-Cl, pH 8.7, 2 mM MgCl_2 , 0.1% Tween 20 and 0.5 units AmpliTaq DNA polymerase (Cetus, Ca., USA) making up a total volume of 50 μ l. The temperature profile included a 0.5 min. denaturation step at 95°C and a 1.5 min. annealing/extension step at 70°C, these steps were repeated 30 times. A GeneAmp PCR System 9600 (Perkin Elmer, Ca, USA) was used for both lysing the bacterial colony and running the reactions. The PCR product was immobilized on paramagnetic beads (Isc, T., *et al* (1988)

SUBSTITUTE SHEET

loc. cit.) with covalently coupled streptavidin, Dynabeads M280. The beads were used as described by the manufacturer (Dynal AS, Norway). Single stranded DNA was obtained by removing the supernatant after incubation of the immobilized PCR product in 0.10 M NaOH for 10 minutes. The immobilized single stranded DNA was washed with 50 μ l 10 mM Tris-Cl (pH 7.5), 1 mM EDTA, 2 M NaCl, followed by 50 μ l 10 mM Tris-Cl (pH 7.5). After washing, 20 mM Tris-Cl (pH 7.5), 8 mM MgCl_2 and 1 pmol sequencing primer were added to a final volume of 13 μ l. The mixture was incubated at 65°C for 5 minutes and then cooled to room temperature.

Mini-sequencing

The dideoxynucleotide incorporation reactions were performed in a mixture of 1 μ l (1/13 of a 50 μ l PCR amplification reaction) of the template/primer-fragment immobilized on paramagnetic beads, 0.13 units Sequase version 2.0 (United States Biochemical, USA), 0.5 μ l 10 mM of a single ddNTP, and a buffer containing 25 mM Tris-Cl (pH 7.5), 12.5 mM MgCl_2 and 2.5 mM DTT in a final volume of 10 μ l. After incubation at room temperature for 5 minutes, the beads were washed with 30 μ l 10 mM Tris-Cl (pH 7.5), 1 mM EDTA, 2 M NaCl, 1% Tween 20 followed by 50 μ l 10 mM Tris-Cl (pH 7.5), 1 mM EDTA, 2 M NaCl and finally with 50 μ l 10 mM Tris-Cl (pH 7.5). The volume was adjusted to 5 μ l with 10 mM Tris-Cl (pH 7.5). Control fragments were incubated with DNA polymerase in the absence of ddNTPs and zero control fragments in the presence of all ddNTPs. The different samples were subsequently analyzed with the EMAS.

ELISA

Samples from the above described mini-sequencing preincubation were assayed for full primer extension by

SUBSTITUTE SHEET

the ELIIDA. The assay was performed using an IKB 1250 luminometer and a potentiometric recorder. The luminometer was calibrated to give a response of 10 mV for the internal light standard. The luminescence output was calibrated by the addition of a known amount of ATP or ppi. The reaction was carried out at room temperature. The standard assay volume was 0.2 ml and contained the following components: 0.1 M Tris-acetate (pH 7.75), 2 mM EDTA, 10 mM magnesium acetate, 0.11 MSA, 1 mM DTT, 0.4 µg/ml polyvinylpyrrolidone 360,000, 2 µM dNTP, 100 µg/ml D-luciferin (Biocorb, Finland), 4 µg/ml L-luciferin (Biocorb, Finland), 0.3 units/ml ATP-sulphurylase (Sigma, USA) and purified luciferase (Enzygnatix, UK). The amount of luciferase used gave a response of 1 V for 100 pmol ATP in a volume of 1 ml. After five minutes of preincubation, adenosine 5'-phosphosulfate, NaP and dNTP were added to final concentrations of 2 µM, 5 mM and 0.4 mM, respectively. The reaction was started after the addition of 5 µl of template/primer-fragments, taken from the dideoxy incorporation, by the addition of 0.13 units of Sequenase. The reaction was completed within 5 minutes.

RESULTS

Principle of the mini-sequencing method

The principle of the mini-sequencing method is outlined in Fig. 1 in which the presence or absence of a T residue is investigated. The specific DNA-fragment of interest is amplified by PCR with one of the primers biotinylated in the 5' end. The PCR-amplified DNA is immobilized on magnetic beads containing covalently coupled streptavidin and subsequently converted into single stranded form by washing with NaOH, and a primer is annealed to the single stranded DNA. The template/primer-fragments are then divided into four

different aliquots which are separately treated with one of the four dNTPs in the presence of the polymerase. After the reaction, the resulting fragments are washed and used as substrates in a primer extension reaction with all four dNTPs present (see Fig. 1). The progress of the DNA-directed polymerisation reactions are monitored with the ELIIDA. Incorporation of a dideoxynucleotide in the first reaction will prevent the formation of pyrophosphate during the subsequent "chase" reaction. In contrast, no dideoxynucleotide incorporation gives extensive pyrophosphate release during the "chase" reaction and this will lead to generation of light through the ELIIDA reactions. From the ELIIDA results, the first base after the primer is easily deduced. It is also possible to include both a negative control, which is incubated with all dNTPs, and a positive control, which is incubated with DNA polymerase in the absence of dNTPs.

20 Mini-sequencing of a specific DNA-fragment

Incorporation of a single dNTP was observed only when the complementary dideoxynucleotide (ddNTP) was present during the polymerase reaction. No incorporation of noncomplementary bases was observed under the conditions used. The formation of ppi was detected by the ELIIDA during the "chase" reaction only when template/primer-fragments were incubated with noncomplementary bases. When a complementary base was incorporated, no extension of the DNA was possible due to the lack of a free 3' OH group. The same result as above was obtained if the DNA-fragments (in the first step) were incubated with four different mixtures of three ddNTPs (not shown). It is important to note that a DNA polymerase lacking exonuclease activity must be used to obtain clean signals, although it is known that exonuclease activity of certain polymerases can be

- 23 -

suppressed, e.g. by fluoride ions. It is also important to use low concentrations of nucleotides (0.05-5 μ M) to avoid incorporation of non-complementary bases (data not shown).

5

Sensitivity

In the experiments presented above 1/13th of a 50 μ l PCR amplification reaction was used per ELISA test. However, both lower and higher amounts can be used. The initial rate and the extent of ppi formation during primer extension of a 161 bases long DNA-fragment as a function of DNA concentration was determined. Both the initial rate and the extent of ppi formed in the ELISA are proportional to the DNA concentration in the interval tested (1/130 to 2/13 of a 50 μ l PCR amplification reaction). The amount of DNA could be further increased as well as the binding capacity of the solid support to increase the signal of the assay. The upper limit for the present assay (in a total volume of 200 μ l) is 200 pmol ppi formed. The lower limit is mainly determined by the length of the DNA-fragment used, (as the signal is proportional to the amount of nucleotides incorporated during the primer extension reaction), the volume used and by contamination of ppi in the different solutions. Both these latter factors can be modified if necessary.

25

SUBSTITUTE SHEET

- 24 -

Claims

1. A method of identification of the base in a target position in a DNA sequence wherein sample DNA is subjected to amplification; the amplified DNA is immobilised and then subjected to strand separation, the non-immobilised strand being removed and an extension primer, which hybridises to the immobilised DNA immediately adjacent to the target position, is provided; each of four aliquots of the immobilised single stranded DNA is then subjected to a polymerase reaction in the presence of a dideoxynucleotide, each aliquot using a different dideoxynucleotide whereby only the dideoxynucleotide complementary to the base in the target position becomes incorporated; the four aliquots are then subjected to extension in the presence of all four dideoxynucleotides, whereby in each aliquot the DNA which has not reacted with the dideoxynucleotide is extended to form double stranded DNA while the dideoxy-blocked DNA remains as non-extended DNA, followed by identification of the double stranded and/or non-extended DNA to indicate which dideoxynucleotide was incorporated and hence which base was present in the target position.
2. A method as claimed in claim 1 in which the sample DNA is amplified by *in vitro* amplification reaction using a first primer which is immobilised or is provided with means for immobilisation.
3. A method as claimed in claim 2 in which said first primer includes a region which, in double stranded form, contains a recognition site for a DNA binding protein carrying a label and formation of double stranded DNA by chain extension is identified by binding to said labelled protein.

SUBSTITUTE SHEET

- 25 -

- 26 -

4. A method as claimed in claim 2 or claim 3 in which the said first primer carries biotin as means for immobilisation.

directly adjacent to the 3' end of the primer;

(b) a polymerase;

5. A method as claimed in any of claims 2 to 4 in which the *in vitro* amplification uses a second primer hybridising to a region A at the 3' terminus of the target DNA and/or to a region B extending 3' from region A, said second primer having a 3' terminal sequence which hybridises to at least a portion of regions A and/or B of the target sequence while having at its 5' end a sequence substantially identical to A, said amplification producing double-stranded target DNA having at the 3'-end of the target sequence, in the

(c) deoxynucleotides and dideoxynucleotides; and
(d) optionally a solid support.

9. A kit as claimed in claim 8 additionally including at least the following components:

(i) a pair of primers for PCR at least one primer having means permitting immobilisation of said primer;

(ii) a polymerase which is preferably heat stable, for example *Taq* polymerase;

(iii) buffers for the PCR reaction; and

(iv) deoxynucleotides.

6. A method as claimed in any of the preceding claims in which identification of the formation of double stranded DNA is effected by detection or estimation of pyrophosphate liberated in the chain extension reaction.


7. A method as claimed in claim 6 in which pyrophosphate is detected or estimated by the luciferase/luciferin reaction wherein emission of light is an indicator or measure of pyrophosphate.

8. A kit for carrying out the method as claimed in claim 1 comprising at least the following components:


(a) a test specific extension primer which hybridises to sample DNA so that the target position is

SUBSTITUTE SHEET

SUBSTITUTE SHEET





SUBSTITUTE SHEET



SUBSTITUTE SHEET

3/4

4/4

**FIG. 4****Mini Sequencing Results**

SUBSTITUTE SHEET

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

PCT/EP 93/01203

International Applications No

of recent classifications applied, national and

Int. Cl. 5 C12Q/18

<p>1. CLASSIFICATION OF SUBJECT MATTER of recent classifications applied, national and</p> <p>Int. Cl. 5 C12Q/18</p>																			
<p>2. ARTICLES SEARCHED</p>																			
<p>3. CLASSIFICATION SYSTEM</p> <p>Machine Documentations searched</p> <p>Classification System</p> <p>Int. Cl. 5 C12Q</p>																			
<p>4. DOCUMENTS SEARCHED</p> <p>Documents searched after each Minimum Documentation to the Extent that such Documents are located in the field Search⁴</p>																			
<p>5. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Number of Documents, 15 with indicators, where appropriate, of the relevant passages²</th> <th>Reference to Class No. 13</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>EP A. 0 412 083 (GERTIN & CIE) 13 February 1993 see abstract; claims</td> <td>8</td> </tr> <tr> <td>A</td> <td>WO A. 8 909 283 (HYMAN E. D.) October 1989 see page 1, line 29 - page 3, line 33 see page 8, line 9 - line 29; claims</td> <td>1,6</td> </tr> <tr> <td>A</td> <td>WO A. 8 912 063 (THE UNITED STATES OF AMERICA) 14 December 1989 see the whole document</td> <td>1,6</td> </tr> <tr> <td>A</td> <td>WO A. 9 309 305 (OMAL AS) 29 January 1993 see claim 11</td> <td>1,2</td> </tr> <tr> <td>P, X</td> <td></td> <td>8,9</td> </tr> </tbody> </table>		Category	Number of Documents, 15 with indicators, where appropriate, of the relevant passages ²	Reference to Class No. 13	X	EP A. 0 412 083 (GERTIN & CIE) 13 February 1993 see abstract; claims	8	A	WO A. 8 909 283 (HYMAN E. D.) October 1989 see page 1, line 29 - page 3, line 33 see page 8, line 9 - line 29; claims	1,6	A	WO A. 8 912 063 (THE UNITED STATES OF AMERICA) 14 December 1989 see the whole document	1,6	A	WO A. 9 309 305 (OMAL AS) 29 January 1993 see claim 11	1,2	P, X		8,9
Category	Number of Documents, 15 with indicators, where appropriate, of the relevant passages ²	Reference to Class No. 13																	
X	EP A. 0 412 083 (GERTIN & CIE) 13 February 1993 see abstract; claims	8																	
A	WO A. 8 909 283 (HYMAN E. D.) October 1989 see page 1, line 29 - page 3, line 33 see page 8, line 9 - line 29; claims	1,6																	
A	WO A. 8 912 063 (THE UNITED STATES OF AMERICA) 14 December 1989 see the whole document	1,6																	
A	WO A. 9 309 305 (OMAL AS) 29 January 1993 see claim 11	1,2																	
P, X		8,9																	
<p>6. SUMMARY OF THE INVENTION</p> <p>7. CLAIMS</p> <p>8. ABSTRACT</p> <p>9. REFERENCES</p> <p>10. OTHER INFORMATION</p> <p>11. STATE OF THE ART</p> <p>12. STATE OF THE ART</p> <p>13. STATE OF THE ART</p> <p>14. STATE OF THE ART</p> <p>15. STATE OF THE ART</p> <p>16. STATE OF THE ART</p> <p>17. STATE OF THE ART</p> <p>18. STATE OF THE ART</p> <p>19. STATE OF THE ART</p> <p>20. STATE OF THE ART</p> <p>21. STATE OF THE ART</p> <p>22. STATE OF THE ART</p> <p>23. STATE OF THE ART</p> <p>24. STATE OF THE ART</p> <p>25. STATE OF THE ART</p> <p>26. STATE OF THE ART</p> <p>27. STATE OF THE ART</p> <p>28. STATE OF THE ART</p> <p>29. STATE OF THE ART</p> <p>30. STATE OF THE ART</p> <p>31. STATE OF THE ART</p> <p>32. STATE OF THE ART</p> <p>33. STATE OF THE ART</p> <p>34. STATE OF THE ART</p> <p>35. STATE OF THE ART</p> <p>36. STATE OF THE ART</p> <p>37. STATE OF THE ART</p> <p>38. STATE OF THE ART</p> <p>39. STATE OF THE ART</p> <p>40. STATE OF THE ART</p> <p>41. STATE OF THE ART</p> <p>42. STATE OF THE ART</p> <p>43. STATE OF THE ART</p> <p>44. STATE OF THE ART</p> <p>45. STATE OF THE ART</p> <p>46. STATE OF THE ART</p> <p>47. STATE OF THE ART</p> <p>48. STATE OF THE ART</p> <p>49. STATE OF THE ART</p> <p>50. STATE OF THE ART</p> <p>51. STATE OF THE ART</p> <p>52. STATE OF THE ART</p> <p>53. STATE OF THE ART</p> <p>54. STATE OF THE ART</p> <p>55. STATE OF THE ART</p> <p>56. STATE OF THE ART</p> <p>57. STATE OF THE ART</p> <p>58. STATE OF THE ART</p> <p>59. STATE OF THE ART</p> <p>60. STATE OF THE ART</p> <p>61. STATE OF THE ART</p> <p>62. STATE OF THE ART</p> <p>63. STATE OF THE ART</p> <p>64. STATE OF THE ART</p> <p>65. STATE OF THE ART</p> <p>66. STATE OF THE ART</p> <p>67. STATE OF THE ART</p> <p>68. STATE OF THE ART</p> <p>69. STATE OF THE ART</p> <p>70. STATE OF THE ART</p> <p>71. STATE OF THE ART</p> <p>72. STATE OF THE ART</p> <p>73. STATE OF THE ART</p> <p>74. STATE OF THE ART</p> <p>75. STATE OF THE ART</p> <p>76. STATE OF THE ART</p> <p>77. STATE OF THE ART</p> <p>78. STATE OF THE ART</p> <p>79. STATE OF THE ART</p> <p>80. STATE OF THE ART</p> <p>81. STATE OF THE ART</p> <p>82. STATE OF THE ART</p> <p>83. STATE OF THE ART</p> <p>84. STATE OF THE ART</p> <p>85. STATE OF THE ART</p> <p>86. STATE OF THE ART</p> <p>87. STATE OF THE ART</p> <p>88. STATE OF THE ART</p> <p>89. STATE OF THE ART</p> <p>90. STATE OF THE ART</p> <p>91. STATE OF THE ART</p> <p>92. STATE OF THE ART</p> <p>93. STATE OF THE ART</p> <p>94. STATE OF THE ART</p> <p>95. STATE OF THE ART</p> <p>96. STATE OF THE ART</p> <p>97. STATE OF THE ART</p> <p>98. STATE OF THE ART</p> <p>99. STATE OF THE ART</p> <p>100. STATE OF THE ART</p>																			

Form PCT/EP 93/01203 (first sheet) (January 1993)

PCT/EP 93/01203

International Applications No

of recent classifications applied, national and

Int. Cl. 5 C12Q/18

<p>1. CLASSIFICATION OF SUBJECT MATTER of recent classifications applied, national and</p> <p>Int. Cl. 5 C12Q/18</p>							
<p>2. ARTICLES SEARCHED</p>							
<p>3. CLASSIFICATION SYSTEM</p> <p>Machine Documentations searched</p> <p>Classification System</p> <p>Int. Cl. 5 C12Q</p>							
<p>4. DOCUMENTS SEARCHED</p> <p>Documents searched after each Minimum Documentation to the Extent that such Documents are located in the field Search⁴</p>							
<p>5. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Number of Documents, 15 with indicators, where appropriate, of the relevant passages²</th> <th>Reference to Class No. 13</th> </tr> </thead> <tbody> <tr> <td>P, X</td> <td>ANALYTICAL BIOCHEMISTRY vol. 208, no. 1, January 1993, NEW YORK US pages 171 - 175 P. NITEN ET AL.</td> <td>1,2,6</td> </tr> </tbody> </table>		Category	Number of Documents, 15 with indicators, where appropriate, of the relevant passages ²	Reference to Class No. 13	P, X	ANALYTICAL BIOCHEMISTRY vol. 208, no. 1, January 1993, NEW YORK US pages 171 - 175 P. NITEN ET AL.	1,2,6
Category	Number of Documents, 15 with indicators, where appropriate, of the relevant passages ²	Reference to Class No. 13					
P, X	ANALYTICAL BIOCHEMISTRY vol. 208, no. 1, January 1993, NEW YORK US pages 171 - 175 P. NITEN ET AL.	1,2,6					

Form PCT/EP 93/01203 (first sheet) (January 1993)

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. EP 9301203
SA 74813

This annex lists the patent family members relating to the patent document cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EPO file as
The European Patent Office is in no way liable for errors or omissions which are merely given for the purpose of information. 27/09/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0412883	13-02-91	FR-A- 2650840 AU-A- 6180190 CA-A- 2038932 WO-A- 4102887 JP-T- 4926866	15-02-91 11-03-91 12-02-91 21-02-91 28-05-91
WO-A-8909283	05-10-89	US-A- 4971903 AU-A- 3354689	20-11-90 16-10-89
WO-A-8912063	14-12-89	AU-A- 3635089 EP-A- 0418320 JP-T- 3503001	05-01-90 27-03-91 11-07-91
WO-A-3308305	29-04-93	None	